Growth signals Qbtech has expanded its U.S. presence with a Houston headquarters and plans to hire locally, indicating potential sales opportunities in the North American market and for enterprise-level ADHD testing solutions.

Leadership transition Recent interim CEO appointment after long-time leadership suggests a period of strategic realignment and potential new partnerships or pilots; use this window to propose expansions in workflow integrations and enterprise deployments.

Clear product moat FDA and MDR-cleared QbCheck objectively measures ADHD symptoms across a broad age range (6-60), offering a robust value proposition for clinics seeking reliable diagnostic and treatment-monitoring tools to replace or augment traditional assessments.

Nonprofit access QbAccess program lowers barriers for nonprofit healthcare organizations to access ADHD testing, presenting a sales angle for public health networks, academic medical centers, and community clinics seeking scalable, cost-effective solutions.

Clinical adoption Dedicated clinical advisors support onboarding and training, enabling faster time-to-value and higher clinician adoption; leverage this to upsell integration services, data reporting capabilities, and remote/clinic workflow optimizations.